Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 22, 2026, 8:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 164 matching trials from the live ClinicalTrials.gov search.
Conditions
Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Myxofibrosarcoma, Metastatic Sarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Unresectable Dedifferentiated Liposarcoma, Unresectable Leiomyosarcoma, Unresectable Myxofibrosarcoma, Unresectable Sarcoma, Unresectable Synovial Sarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pegylated Liposomal Doxorubicin Hydrochloride, Peposertib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Los Angeles, California • Aurora, Colorado • Miami, Florida + 11 more
Conditions
Lung Cancer
Interventions
Small RNA-based lung cancer assay
Diagnostic Test
Lead sponsor
Hummingbird Diagnostics
Industry
Eligibility
50 Years to 80 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
11
States / cities
Atlanta, Georgia • Baton Rouge, Louisiana • Boston, Massachusetts + 7 more
Conditions
Coronary Disease
Interventions
Cannon Aquilion ONE CT system
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Lung Cancer, Lung Cancer Screening
Interventions
Stepped Reminders, Patient Education
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
50 Years to 78 Years
Enrollment
1,837 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Kidney Stones
Interventions
low dose radiation abdomen/pelvis CT scan (stone protocol), Blood draw, 24 hour urine collection
Diagnostic Test · Procedure · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Breast Cancer
Interventions
Breast MRI, Breast-Q© questionnaire, Multi-Beam IMRT
Device · Behavioral · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 4 more
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites

NCT03315910
Conditions
Smoking Cessation
Interventions
Motivational Interviewing (MI), Nicotine Replacement Therapy (NRT), Nicotine Lozenge, Message Framing, saliva sample
Behavioral · Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
50 Years to 80 Years
Enrollment
807 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
18
States / cities
Los Angeles, California • Walnut Creek, California • La Grange, Georgia + 14 more
Conditions
Steatosis of Liver, NASH - Nonalcoholic Steatohepatitis
Interventions
Fibroscan of Liver, Low-dose non-contrast CT
Device · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
55 Years to 80 Years
Enrollment
340 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Conditions
Adrenocortical Adenoma, Endometrial Stromal Sarcomas
Interventions
MRI, CT or ultrasound was permitted if MRI was contraindicated, Dexamethasone Supression Test, Sonogram, Biopsy, BGG492
Procedure · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Tallahassee, Florida • Baltimore, Maryland • Hoffman, New Jersey + 1 more
Conditions
Lung Cancer
Interventions
Not listed
Lead sponsor
Innovis LLC
Industry
Eligibility
18 Years to 79 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
3
States / cities
Celebration, Florida • Baltimore, Maryland • Nashville, Tennessee
Conditions
High Risk of Developing Lung Cancer
Interventions
CT scan & Early CDT Lung test, CT scan & Early CDT Lung test
Radiation · Other
Lead sponsor
National Jewish Health
Other
Eligibility
50 Years to 75 Years
Enrollment
1,361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Denver, Colorado
Recruiting No phase listed Observational

Mg OSTEOCRETE Post-Treatment Outcomes

NCT06720142
Conditions
Cancer of Bone, Trauma, Aseptic Loosening of Orthopaedic Hardware
Interventions
Mg OSTEOCRETE as a bone void filler
Device
Lead sponsor
Santiago Lozano-Calderon
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
HPV-Associated Oropharyngeal Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Stage, HPV-Related Squamous Cell Carcinoma, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Clinical Stage, HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Pathologic Stage
Interventions
NavDx HPV ctDNA Testing, Radiotherapy, Chemotherapy drug
Device · Radiation · Drug
Lead sponsor
Jonathan Schoenfeld, MD, MPH
Other
Eligibility
22 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Multiple Pulmonary Emboli
Interventions
Low-Dose IV Contrast, Siemens Sensation 64-MDCT scanner., Visipaque 320 non-ionic isoosmolar contrast agent
Procedure · Device · Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Recruiting No phase listed Observational Accepts healthy volunteers

Lung Cancer Biomarkers and Screening

NCT00301119
Conditions
Lung Cancer
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
50 Years and older
Enrollment
3,606 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2030
U.S. locations
1
States / cities
New York, New York
Conditions
Carcinoma, Squamous Cell of Head and Neck
Interventions
Ficlatuzumab, Cisplatin, Intensity Modulated Radiotherapy (IMRT)
Drug · Radiation
Lead sponsor
Julie E. Bauman, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Conditions
Neuroendocrine Tumors
Interventions
PET/CT Imaging, 68Ga-DOTA-JR11, 177Lu-DOTA-JR11
Device · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
New York, New York
Conditions
Coronary Artery Disease, Ischemia
Interventions
Computed Tomography Angiography
Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Sarcoidosis
Interventions
Fluorodeoxyglucose, Rubidium, FDG-PET/CT with Rb82 Myocardial Perfusion Imaging
Drug · Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
piflufolastat F 18
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
St Louis, Missouri • Omaha, Nebraska
Conditions
Family History of Lung Cancer
Interventions
CT scan, Sybil
Diagnostic Test · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Mantle Cell Lymphoma
Interventions
Ofatumumab (This arm is closed), Ofatumumab + Bendamustine
Biological · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more
Completed Not applicable Interventional Results available

FDG-PET Imaging in Young Cystic Fibrosis Patients

NCT00846053
Conditions
Cystic Fibrosis
Interventions
FDG-PET
Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years to 21 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Sarcoma, Melanoma
Interventions
Pro-GRID
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia